Text Size

Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops

Daull P., Barabino S., Feraille L., Kessal K., Docquier M., Parsadaniantz S.M., Baudouin C., Garrigue J.-S.

  • 2019
  • Current Eye Research
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology


  • Categories

    Preclinical development

  • Affiliations

    Novagali Innovation Center, SANTEN SAS, Novagali Innovation Center, Evry Cedex, France; Ocular Surface & Dry Eye Center, Ospedale L. Sacco, University of Milan, Milan, Italy; Iris Pharma, Les Nertières, Allée Hector Pintus, La Gaude, France; Vision Institute UMR S 968, UMR 7210 CNRS, Paris Sorbonne Universités, Paris, France; iGE3, University of Geneva Medical School, Geneva 4, Switzerland; CHNO XV-XX Hospital, Paris, France

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022